After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound

Nicole DeFeudis

Editor

More than any other year in recent memory, 2020 was a rollercoaster of highs and lows —mostly lows. Just ask San Francisco’s Nektar: Despite ditching …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Af­ter an up-and-down year, Nek­tar watch­es de­vel­op­ment head Wei Lin walk away as it pur­sues pipeline re­bound

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound